A topical anti-infective
ZHAWOC6027 ist a novel drug candidate against skin infections. In order to use it successfully, various things need to be optimised.
Description
ZHAWOC6027, a novel drug candidate against skin infections, requires an optimized CMC, formulation, appropriate dosing regimens, regulatory tox package and registration. To this end, the synthesis and formulation of the active ingredient are being optimized in terms of medicinal chemistry and regulatory work packages are being processed.
Key Data
Projectlead
Project team
Dr. Dimanthi Pliatsika, Dr. Alessandra Tania Zizzari
Project partners
BACOBA AG; Fachhochschule Nordwestschweiz FHNW
Project status
completed, 05/2019 - 04/2021
Funding partner
Innovationsprojekt / Projekt Nr. 34227.1 IP-LS
Project budget
2'074'501 CHF
Publications
-
Dissecting structural requirements of leucinostatin A derivatives for antiprotozoal activity and mammalian toxicity
2025 Rimle, Lukas; Pliatsika, Dimanthi; Arnold, Noëlle; Kurth, Sandra; Kaiser, Marcel; Mäser, Pascal; Kemmler, Michael; Adams, Michael; Riedl, Rainer; von Ballmoos, Christoph
-
Antiprotozoische Struktur‐Aktivitäts‐Beziehungen von synthetischen Leucinostatin‐Derivaten und Aufklärung ihres Wirkprinzips
2021 Brand, Michael; Wang, Lei; Agnello, Stefano; Gazzola, Silvia; Gall, Flavio; Raguž, Luka; Kaiser, Marcel; Schmidt, Remo S.; Ritschl, Amélie; Jelk, Jennifer; Hemphill, Andrew; Mäser, Pascal; Bütikofer, Peter; Adams, Michael; Riedl, Rainer
-
Antiprotozoal structure–activity relationships of synthetic leucinostatin derivatives and elucidation of their mode of action
2021 Brand, Michael; Wang, Lei; Agnello, Stefano; Gazzola, Silvia; Gall, Flavio; Raguž, Luka; Kaiser, Marcel; Schmidt, Remo S.; Ritschl, Amélie; Jelk, Jennifer; Hemphill, Andrew; Mäser, Pascal; Bütikofer, Peter; Adams, Michael; Riedl, Rainer
Einsiedlerstrasse 31
8820 Wädenswil